Abetalipoproteinemia

Revision as of 15:55, 17 September 2013 by Rim Halaby (talk | contribs) (→‎Treatment)
Jump to navigation Jump to search

WikiDoc Resources for Abetalipoproteinemia

Articles

Most recent articles on Abetalipoproteinemia

Most cited articles on Abetalipoproteinemia

Review articles on Abetalipoproteinemia

Articles on Abetalipoproteinemia in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Abetalipoproteinemia

Images of Abetalipoproteinemia

Photos of Abetalipoproteinemia

Podcasts & MP3s on Abetalipoproteinemia

Videos on Abetalipoproteinemia

Evidence Based Medicine

Cochrane Collaboration on Abetalipoproteinemia

Bandolier on Abetalipoproteinemia

TRIP on Abetalipoproteinemia

Clinical Trials

Ongoing Trials on Abetalipoproteinemia at Clinical Trials.gov

Trial results on Abetalipoproteinemia

Clinical Trials on Abetalipoproteinemia at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Abetalipoproteinemia

NICE Guidance on Abetalipoproteinemia

NHS PRODIGY Guidance

FDA on Abetalipoproteinemia

CDC on Abetalipoproteinemia

Books

Books on Abetalipoproteinemia

News

Abetalipoproteinemia in the news

Be alerted to news on Abetalipoproteinemia

News trends on Abetalipoproteinemia

Commentary

Blogs on Abetalipoproteinemia

Definitions

Definitions of Abetalipoproteinemia

Patient Resources / Community

Patient resources on Abetalipoproteinemia

Discussion groups on Abetalipoproteinemia

Patient Handouts on Abetalipoproteinemia

Directions to Hospitals Treating Abetalipoproteinemia

Risk calculators and risk factors for Abetalipoproteinemia

Healthcare Provider Resources

Symptoms of Abetalipoproteinemia

Causes & Risk Factors for Abetalipoproteinemia

Diagnostic studies for Abetalipoproteinemia

Treatment of Abetalipoproteinemia

Continuing Medical Education (CME)

CME Programs on Abetalipoproteinemia

International

Abetalipoproteinemia en Espanol

Abetalipoproteinemia en Francais

Business

Abetalipoproteinemia in the Marketplace

Patents on Abetalipoproteinemia

Experimental / Informatics

List of terms related to Abetalipoproteinemia

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Synonyms and keywords: Acanthocytosis, Bassen-Kornzweig syndrome, apolipoprotein B deficiency, microsomal triglyceride transfer protein deficiency, MTP deficiency

Overview

Abetalipoproteinemia is a rare autosomal recessive genetic disorder that interferes with the normal absorption of fat and fat soluble vitamins from food.

Features

Abetalipoproteinemia is an inherited disorder that affects the absorption of dietary fats, cholesterol, and certain vitamins. People affected by this disorder are not able to make certain lipoproteins, which are molecules that consist of proteins combined with cholesterol and particular fats called triglycerides. This leads to a multiple vitamin deficiency, affecting the fat soluble vitamin A, vitamin D, vitamin E, and vitamin K. However, many of the observed effects are due to vitamin E deficiency in particular.

The signs and symptoms of abetalipoproteinemia appear in the first few months of life. They can include failure to gain weight and grow at the expected rate (failure to thrive); diarrhea; abnormal star-shaped red blood cells (acanthocytosis); and fatty, foul-smelling stools (steatorrhea). Specifically the stool may contain large chunks of fat and or blood. Other features of this disorder may develop later in childhood and often impair the function of the nervous system. They can include poor muscle coordination, difficulty with balance and movement (ataxia), and progressive degeneration of the light-sensitive layer (retina) at the back of the eye that can progress to near-blindness. Adults in their thirties or forties may have increasing difficulty with balance and walking. Many of the signs and symptoms of abetalipoproteinemia result from a severe vitamin deficiency, especially vitamin E deficiency which typically results in eye problems with degeneration of the spinocerebellar and dorsal columns tracts.

Diagnosis

The inability to absorb fat in the ileum will result in steatorrhea, or fat in the stool. As a result, this can be clinically diagnosed when foul smelling stool is encountered. Low plasma chylomicron levels are also characteristic. Acanthocytes are seen on blood smear.

Pathology

Acanthocytes (Abetalipoproteinemia)[1]


Pathophysiology

Two genes have been identified in which mutations are associated with this disorder: microsomal triglyceride transfer protein (MTTP) and apolipoprotein B (ApoB).

The MTTP gene provides instructions for making a protein called microsomal triglyceride transfer protein, which is essential for creating beta-lipoproteins. These lipoproteins are necessary for the absorption of fats, cholesterol, and fat-soluble vitamins from the diet and the efficient transport of these substances in the bloodstream. Most of the mutations in this gene lead to the production of an abnormally short microsomal triglyceride transfer protein, which prevents the normal creation of beta-lipoproteins in the body. MTTP associated mutations are inherited in an autosomal recessive pattern, which means both copies of the gene must be faulty to produce the disease.

There is an absence of apolipoprotein B. On intestinal biopsy, vacuoles containing lipids are seen in enterocytes. Since there is no or little assimilation of chylomicrons, their levels in plasma remains low. This disorder may also result in fat accumulation in the liver (hepatic steatosis). Because the epithelial cells of the bowel lack the ability to place fats into chylomicrons, lipids accumulate at the surface of the cell, crowding the functions that are necessary for proper absorption.

Treatment

  • Treatment normally consists of rigorous dieting, involving mass amounts of vitamin E. Vitamin E helps the body restore and produce lipoproteins, which people with abetalipoprotenimia usually lack. Vitamin E also helps keep skin and eyes healthy, which studies show that many males whom are affected will have vision problems later on in life. Dyspraxia and muscle weakness is usually combated with psysiotherapy, or occupational therapy.
  • Dietary restriction of triglycerides has also been useful.

References

Template:Endocrine, nutritional and metabolic pathology

Template:WikiDoc Sources